Duke logo

UM1 10129 Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors - Clinical Trial

What is the Purpose of this Study?

We are doing this study to test any good and/or bad effects of the study drug, olaparib.

What is the Condition Being Studied?

Tumor with a gene called IDH1 or IDH2, which has grown or recurred

Who Can Participate in the Study?

Adults who:
- Have cholangiocarcinoma or other solid malignant tumor that has grown with standard therapy
- Have a tumor that is can be easily biopsy and must be willing to have up to 3 biopsies
- Have had no previous treatment with olaparib or any other PARP inhibitor

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Have one office visit every 28 days
- Have up to 3 biopsies
- Take the study drug, olaparib
- Give blood samples
- Have CT or MRI scans

Study Details

Full Title
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors (10129)
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00102376
NCT:NCT03212274
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698